Boehringer Gets Option To Buy ViraTherapeutics And Cancer Virus Therapy
The German pharma agreed to pay up to €210m to investigate ViraTherapeutics' lead candidate, VSV-GP, alone and in combination, with an option to buy ViraTherapeutics depending on the outcome of Phase I studies.
You may also be interested in...
Boehringer Ingelheim more than doubled its venture fund from €100m to €250m, giving BI more access to early innovation via new capital, two new investment managers and a West Coast presence.
Trying to catch up with peers in both immuno-oncology and NASH, the German pharma has assigned Sapountzis to lead its US business development efforts. At BIO, he outlined his strategy and goals.
A review of biopharma start-up dealmaking and financing from July through September 2016, based on data from Strategic Transactions.